PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

46 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
21.
Neff, F.* et al.: Targeting notch for myeloid reprogramming in pancreatic cancer. Oncol. Res. Treat. 39, 16 (2016)
22.
Trajkovic-Arsic, M.* et al.: Identification of metabolic changes in pancreatic ductal adenocarcinoma. Oncol. Res. Treat. 39, 76-77 (2016)
23.
Willier, S.* et al.: Role of Thyroid Receptor Interacting Protein 6 (TRIP6) in migration and invasion of Ewing' sarcoma cells. Oncol. Res. Treat. 39, 145 (2016)
24.
Bücklein, V.L. et al.: Intratumoral immune cell infiltration in patients with high-grade soft-tissue sarcoma is associated with tumor grading. Oncol. Res. Treat. 38, 246-247 (2015)
25.
Bücklein, V.L. et al.: Immunotherapeutic strategies for soft-tissue sarcoma: Preclinical results of Natural Killer cell augmentation by ex vivo expansion and use of an anti-GD2 antibody. Oncol. Res. Treat. 38, 149-150 (2015)
26.
Freysoldt, B. et al.: Cotargeting of PIM, PI3K and mTOR in mantle cell lymphoma. Oncol. Res. Treat. 38, 63 (2015)
27.
Garz, A.-K.* et al.: The combination of crenolanib and azacitidine effectively targets leukemia-initiating cells in FLT3-ITD+ AML to overcome protection by the bone marrow niche. Oncol. Res. Treat. 38, 214 (2015)
28.
Habringer, S.* et al.: Very early functional in-vivo imaging to predict response to B cell receptor pathway targeting in lymphoma. Oncol. Res. Treat. 38, 99 (2015)
29.
Hatzl, S.* et al.: Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a. Oncol. Res. Treat. 38, 99 (2015)
30.
Köhnke, T. ; Rechkemmer, S.* ; Bücklein, V.L. ; Hiddemann, W.* & Subklewe, M.: Feasibility of semi-automated MRD analysis by flow cytometry in acute myeloid leukemia. Oncol. Res. Treat. 38, 46 (2015)
31.
Krupka, C. et al.: Combining immune checkpoint inhibition with the CD33 BiTE (R) antibody construct AMG 330 to enhance T cell mediated lysis of primary AML cells. Oncol. Res. Treat. 38, 38 (2015)
32.
Lichtenegger, F.S. et al.: Next-generation dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I trial. Oncol. Res. Treat. 38, 37 (2015)
33.
Zoellner, A.-K.* et al.: The B-cell receptor pathway is highly actived in canine DLBCL cell line CLBL-1. Oncol. Res. Treat. 38, 65 (2015)
34.
Bruns, H.* et al.: Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high grade B-cell lymphoma. Oncol. Res. Treat. 37, 70 (2014)
35.
Harnicek, D. et al.: Hyperthermia combined with trabectedin prolongs G2 cell cycle arrest and reduces cellular survival in human tumor cells. Oncol. Res. Treat. 37, 116 (2014)
36.
Hellmuth, J. et al.: Gastrointestinal Follicular Lymphoma (FL) differs from nodal FL by absence of EZH2 mutations. Oncol. Res. Treat. 37, 75 (2014)
37.
Jansen, L.* et al.: Socio-economic deprivation and cancer survival in Germany. Oncol. Res. Treat. 37, 34 (2014)
38.
Kobold, S.* et al.: Bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. Oncol. Res. Treat. 37, 239 (2014)
39.
Lichtenegger, F.S. et al.: T cell differentiation but not exhaustion in AML. Oncol. Res. Treat. 37, 225 (2014)
40.
Lichtenegger, F.S. et al.: Next-generation dendritic cell vaccination as postremission therapy for AML patients with a non-favorable risk profile. Oncol. Res. Treat. 37, 310 (2014)
▮◀ ◀◀ 1 ... 2 ... 3 ... ▶▶ ▶▮